Protein

Abstract

The present invention provides methods and compositions for screening, diagnosis and prognosis of colorectal cancer, kidney cancer, liver cancer, lung cancer, lymphoid leukaemia (particularly chronic lymphocytic leukaemia), ovarian cancer or pancreatic cancer, for monitoring the effectiveness of colorectal cancer, kidney cancer, liver cancer, lung cancer, lymphoid leukaemia (particularly chronic lymphocytic leukaemia), ovarian cancer or pancreatic cancer treatment, and for drug development.

1 - 93 . (canceled) 
     
     
         94 . A method comprising administering to a patient having increased levels of OGTA076 as compared to a healthy control a composition comprising an affinity reagent capable of specific binding to OGTA076 as defined in SEQ ID No: 1, or a fragment thereof, and a pharmaceutically acceptable diluent or carrier. 
     
     
         95 . The method according to  claim 94 , wherein said patient has colorectal cancer, kidney cancer, liver cancer, lung cancer, lymphoid leukaemia (particularly chronic lymphocytic leukaemia), ovarian cancer or pancreatic cancer, or has increased likelihood of developing colorectal cancer, kidney cancer, liver cancer, lung cancer, lymphoid leukaemia (particularly chronic lymphocytic leukaemia), ovarian cancer or pancreatic cancer. 
     
     
         96 . The method of  claim 94 , wherein said affinity reagent comprises a label. 
     
     
         97 . The method of  claim 95 , wherein said affinity reagent comprises a label. 
     
     
         98 . The method according to  claim 96 , wherein said label is a detectable label or therapeutic moiety. 
     
     
         99 . The method according to  claim 97 , wherein said label is a detectable label or therapeutic moiety. 
     
     
         100 . The method according to  claim 98 , wherein said therapeutic moiety is selected from the group consisting of a cytotoxic moiety and a radioactive isotope. 
     
     
         101 . The method according to  claim 99 , wherein said therapeutic moiety is selected from the group consisting of a cytotoxic moiety and a radioactive isotope. 
     
     
         102 . The method of  claim 94 , wherein said affinity reagent is selected from the group consisting of fusion proteins and antibodies. 
     
     
         103 . The method of  claim 102 , wherein said antibody is a monoclonal antibody, a humanized antibody, a bispecific antibody, a non-fucosylated antibody, an antibody fragment, or an antibody mimetic. 
     
     
         104 . The method of  claim 94 , wherein said affinity reagent has cytotoxicity against OGTA076 antigen expressing cells in the presence of a human complement or in the presence of human immune effector cells. 
     
     
         105 . A method of screening for or diagnosis of, or for monitoring or assessing treatment of or preventing colorectal cancer, kidney cancer, liver cancer, lung cancer, lymphoid leukaemia (particularly chronic lymphocytic leukaemia), ovarian cancer or pancreatic cancer comprising analyzing a sample from a patient for:
 a. the presence or absence; or   b. the quantity;   
       of OGTA076, whereby an increase in the level of OGTA076 as compared to a healthy control is indicative of the presence of or increased likelihood of developing colorectal cancer, kidney cancer, liver cancer, lung cancer, lymphoid leukaemia (particularly chronic lymphocytic leukaemia), ovarian cancer or pancreatic cancer. 
     
     
         106 . The method of  claim 105  which comprises contacting said sample with one or more anti-OGTA076 affinity reagents capable of specific binding to OGTA076 as defined in SEQ ID No: 1, or a fragment or derivative thereof. 
     
     
         107 . The method according to  claim 105 , wherein said analyzing comprises imaging said sample. 
     
     
         108 . The method according to  claim 106 , wherein said analyzing comprises imaging said sample. 
     
     
         109 . The method of  claim 107 , wherein said affinity reagent comprises a detectable label. 
     
     
         110 . The method of  claim 108 , wherein said affinity reagent comprises a detectable label. 
     
     
         111 . The method of  claim 105 , wherein said method comprises detecting OGTA076 mRNA.